Seeking Alpha

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor ...
Yahoo Finance

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

TAMPA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
WFLA News Channel 8

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
Zacks Investment Research on MSN

PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain

Pacira BioSciences PCRX announced results from a pilot study evaluating the unique therapeutic approach of its iovera system ...
Becker's ASC

Ultrasound Guidance Improves Peripheral Nerve Block Success Rate

Ultrasound-guided peripheral nerve blocks have a higher success rate compared to nerve stimulation or other methods, according to a study conducted by the Department of Anesthesiology at Johns Hopkins ...